NCT05261256Completed
Cardiac Impairments Following Pediatric Cardiotoxic Anti-cancer Treatment
Early Detection of Cardiac Impairments Following Cardiotoxic Anti-cancer Treatment During Childhood and Adolescence - A Feasibility Study
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
This study aims at investigating the feasibility of recruitment and application of a method regarding early detection of subclinical changes in cardiac health after completion of acute cancer treatment during childhood and adolescence.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 40 (actual)
- First submitted
- 14 Dec 2021
- Start date
- 1 Feb 2022
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Technical University of Munich
- Diseases
- Childhood cancers
- NCT number
- NCT05261256
What you commit to
- Study type: Observational
- Participants enrolled: 40
- From 1 Feb 2022 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known cardiovascular diseases (incoherent with cardiotoxic treatment)
Other
- Inability to follow study instructions (e.g., mental retardation, language)
- Acute orthopedic injury (e.g., bone fracture) or orthopedic impairments that preclude examination on a bicycle ergometer (e.g., instable prosthetic device)
- All participants receive a basic physical and cardiological examination at rest as part of the study protocol to ensure capability before performing the exercise stress echocardiography.
Who the study is looking for
- Aged between 10 and 25 years
- Body height of ≥1,40m (required for performing the examination on the semi supine bicycle ergometer)
- Signed informed assent (minor participant) and consent (legal guardian and full-aged participant)
- Additional inclusion criteria for participants following cancer treatment:
- Completion of acute cancer treatment with anthracyclines and/or chest radiation
- End of treatment 12 months and five years ago (± three months)
- Medical approval for study participation
- Additional inclusion criteria for healthy control subjects:
- \- Appropriate as matched pair with respect to age and gender
Age in the registry: 10 years to 25 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Preventive Pediatrics, Department of Sport and Health Sciences, Technical University of Munich, Germany Coordinator of this site? Confirm its status | Munich | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.